Joshua H. Hunter

2.0k total citations · 2 hit papers
21 papers, 1.3k citations indexed

About

Joshua H. Hunter is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Joshua H. Hunter has authored 21 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 13 papers in Radiology, Nuclear Medicine and Imaging and 4 papers in Molecular Biology. Recurrent topics in Joshua H. Hunter's work include HER2/EGFR in Cancer Research (14 papers), Monoclonal and Polyclonal Antibodies Research (13 papers) and Peptidase Inhibition and Analysis (4 papers). Joshua H. Hunter is often cited by papers focused on HER2/EGFR in Cancer Research (14 papers), Monoclonal and Polyclonal Antibodies Research (13 papers) and Peptidase Inhibition and Analysis (4 papers). Joshua H. Hunter collaborates with scholars based in United States, Australia and Canada. Joshua H. Hunter's co-authors include Peter D. Senter, Martha E. Anderson, Robert P. Lyon, Svetlana O. Doronina, Jocelyn R. Setter, Tim D. Bovee, Patrick Burke, Mechthild Jonas, Haley D. Neff‐LaFord and Fu Li and has published in prestigious journals such as Angewandte Chemie International Edition, Nature Biotechnology and PLoS ONE.

In The Last Decade

Joshua H. Hunter

21 papers receiving 1.3k citations

Hit Papers

2 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index

2015 390 citations Robert P. Lyon, Tim D. Bovee et al. Nature Biotechnology profile →
Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates

2014 358 citations Robert P. Lyon, Jocelyn R. Setter et al. Nature Biotechnology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joshua H. Hunter United States	13	858	829	551	212	101	21	1.3k
Michael Torgov United States	11	983 1.1×	941 1.1×	639 1.2×	167 0.8×	117 1.2×	19	1.6k
Scott C. Jeffrey United States	16	990 1.2×	967 1.2×	777 1.4×	356 1.7×	113 1.1×	33	1.6k
Barbara A. Leece United States	12	807 0.9×	763 0.9×	386 0.7×	181 0.9×	104 1.0×	17	1.2k
Janis Upeslacis United States	10	595 0.7×	509 0.6×	483 0.9×	275 1.3×	61 0.6×	11	1.2k
Robert P. Lyon United States	22	1.4k 1.7×	1.4k 1.6×	984 1.8×	340 1.6×	162 1.6×	45	2.4k
Jocelyn R. Setter United States	8	791 0.9×	758 0.9×	495 0.9×	219 1.0×	87 0.9×	13	1.2k
Torbjörn Gräslund Sweden	24	450 0.5×	1.1k 1.3×	1.1k 2.0×	52 0.2×	92 0.9×	67	1.7k
Fred Jacobson United States	9	548 0.6×	806 1.0×	774 1.4×	48 0.2×	142 1.4×	11	1.3k
Martha E. Anderson United States	18	1.4k 1.6×	1.1k 1.3×	865 1.6×	280 1.3×	128 1.3×	38	2.1k
Jonathan D. Bargh United Kingdom	9	597 0.7×	549 0.7×	452 0.8×	260 1.2×	73 0.7×	9	1.0k

Countries citing papers authored by Joshua H. Hunter

Since Specialization

Citations

This map shows the geographic impact of Joshua H. Hunter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joshua H. Hunter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joshua H. Hunter more than expected).

Fields of papers citing papers by Joshua H. Hunter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joshua H. Hunter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joshua H. Hunter. The network helps show where Joshua H. Hunter may publish in the future.

Co-authorship network of co-authors of Joshua H. Hunter

This figure shows the co-authorship network connecting the top 25 collaborators of Joshua H. Hunter. A scholar is included among the top collaborators of Joshua H. Hunter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joshua H. Hunter. Joshua H. Hunter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Finau, Glen, Diane Jarvis, Natalie Stoeckl, et al.. (2023). Accounting for Indigenous cultural connections to land: insights from two Indigenous groups of Australia. Accounting Auditing & Accountability Journal. 36(9). 370–389. 9 indexed citations

2.

Larson, Silva, Diane Jarvis, Natalie Stoeckl, et al.. (2022). Piecemeal stewardship activities miss numerous social and environmental benefits associated with culturally appropriate ways of caring for country. Journal of Environmental Management. 326(Pt B). 116750–116750. 16 indexed citations

3.

Meyer, David W., Sara Shum, Mechthild Jonas, et al.. (2020). An in Vitro Assay Using Cultured Kupffer Cells Can Predict the Impact of Drug Conjugation on in Vivo Antibody Pharmacokinetics. Molecular Pharmaceutics. 17(3). 802–809. 23 indexed citations

4.

Li, Fu, Michelle Ulrich, Vincent Feng-Sheng Shih, et al.. (2019). Mouse Strains Influence Clearance and Efficacy of Antibody and Antibody–Drug Conjugate Via Fc–FcγR Interaction. Molecular Cancer Therapeutics. 18(4). 780–787. 37 indexed citations

5.

Hunter, Joshua H., et al.. (2019). Native size-exclusion chromatography-mass spectrometry: suitability for antibody–drug conjugate drug-to-antibody ratio quantitation across a range of chemotypes and drug-loading levels. mAbs. 12(1). 1682895–1682895. 55 indexed citations

6.

Levengood, Matthew R., Xinqun Zhang, Kim K. Emmerton, Joshua H. Hunter, & Peter D. Senter. (2017). Abstract 982: Development of homogeneous dual-drug ADCs: Application to the co-delivery of auristatin payloads with complementary antitumor activities. Cancer Research. 77(13_Supplement). 982–982. 3 indexed citations

7.

Burke, Patrick, Joshua H. Hunter, Julia H. Cochran, et al.. (2017). Abstract 56: Antibody-drug conjugates containing glucuronide-tubulysin payloads display activity in MDR+ and heterogeneous tumor models. Cancer Research. 77(13_Supplement). 56–56. 1 indexed citations

8.

Burke, Patrick, Jocelyn R. Setter, Joshua H. Hunter, et al.. (2016). Development of Novel Quaternary Ammonium Linkers for Antibody–Drug Conjugates. Molecular Cancer Therapeutics. 15(5). 938–945. 45 indexed citations

9.

Burke, Patrick, Scott C. Jeffrey, Joshua H. Hunter, et al.. (2016). Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody–Drug Conjugates. Molecular Cancer Therapeutics. 16(1). 116–123. 110 indexed citations

10.

Li, Fu, Michelle Ulrich, Joshua H. Hunter, et al.. (2016). Abstract 2082: Fc-FcγR interaction impacts the clearance and antitumor activity of antibody-drug conjugates in NSG mice. Cancer Research. 76(14_Supplement). 2082–2082. 2 indexed citations

11.

Levengood, Matthew R., Xinqun Zhang, Joshua H. Hunter, et al.. (2016). Orthogonal Cysteine Protection Enables Homogeneous Multi‐Drug Antibody–Drug Conjugates. Angewandte Chemie International Edition. 56(3). 733–737. 113 indexed citations

12.

Levengood, Matthew R., Xinqun Zhang, Joshua H. Hunter, et al.. (2016). Orthogonal Cysteine Protection Enables Homogeneous Multi‐Drug Antibody–Drug Conjugates. Angewandte Chemie. 129(3). 751–755. 17 indexed citations

13.

Lyon, Robert P., Tim D. Bovee, Svetlana O. Doronina, et al.. (2015). Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index. Nature Biotechnology. 33(7). 733–735. 390 indexed citations breakdown →

14.

Sussman, Django, Leia M. Smith, Martha E. Anderson, et al.. (2014). SGN–LIV1A: A Novel Antibody–Drug Conjugate Targeting LIV-1 for the Treatment of Metastatic Breast Cancer. Molecular Cancer Therapeutics. 13(12). 2991–3000. 104 indexed citations

15.

Lyon, Robert P., Jocelyn R. Setter, Tim D. Bovee, et al.. (2014). Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates. Nature Biotechnology. 32(10). 1059–1062. 358 indexed citations breakdown →

16.

Burke, Patrick, Joshua H. Hunter, Scott C. Jeffrey, et al.. (2014). Abstract 1786: Development and pharmacological properties of PEGylated glucuronide-auristatin linkers. Cancer Research. 74(19_Supplement). 1786–1786. 1 indexed citations

17.

Sussman, Django, Leia M. Smith, Martha E. Anderson, et al.. (2013). Abstract 3962: SGN-LIV1A: a development stage antibody drug-conjugate targeting LIV-1 for the treatment of metastatic breast cancer.. Cancer Research. 73(8_Supplement). 3962–3962. 4 indexed citations

18.

Hunter, Joshua H., et al.. (2009). Catalytic and ligand-binding characteristics of Plasmodium falciparum serine hydroxymethyltransferase. Molecular and Biochemical Parasitology. 168(1). 74–83. 25 indexed citations

19.

Hunter, Joshua H., et al.. (2008). Kinetics and Ligand-Binding Preferences of Mycobacterium tuberculosis Thymidylate Synthases, ThyA and ThyX. PLoS ONE. 3(5). e2237–e2237. 31 indexed citations

20.

Brideau, Christine, et al.. (2004). SOS—A Sample Ordering System for Delivering “Assay-Ready” Compound Plates for Drug Screening. JALA Journal of the Association for Laboratory Automation. 9(3). 123–127. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact